Resveratrol improves cardiovascular function in DOCA-salt hypertensive rats

Current Pharmaceutical Biotechnology

Volumn 12, Issue 3, 2011, Pages 429-436

  Chan, Vincent ^a,b   Fenning, Andrew ^a   Iyer, Abishek ^a   Hoey, Andrew ^b   Brown, Lindsay ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

Collagen; Doca salt; Fibrosis; Hypertrophy; Rats; Resveratrol; Sirtuins

Indexed keywords

DEOXYCORTICOSTERONE ACETATE; RESVERATROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARDIOVASCULAR FUNCTION; ECHOCARDIOGRAPHY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE FIBROSIS; HEART MUSCLE POTENTIAL; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; HYPERTENSION; INFLAMMATORY INFILTRATE; MALE; NONHUMAN; RAT; SYSTOLIC BLOOD PRESSURE; UNINEPHRECTOMY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DESOXYCORTICOSTERONE; FIBROSIS; HEART; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; MINERALOCORTICOIDS; RATS; RATS, WISTAR; SODIUM CHLORIDE, DIETARY; STILBENES; VENTRICULAR REMODELING;

RATTUS;

EID: 79551655242     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111794480552     Document Type: Article

References (44)

1. Baur, J. A.; Sinclair, D. A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5 (6), 493-506.
2. Pervaiz, S.; Holme, A. L.; Aggarwal, B. B.; Anekonda, T. S.; Baur, J. A.; Gojkovic-Bukarica, L.; Ragione, F. D.; Kim, A. L.; Pirola, L.; Saiko, P. Resveratrol: its biologic targets and functional activity. Antioxid. Redox Signal., 2009, 11 (11), 2851-2897.
3. Aggarwal, B. B.; Bhardwaj, A.; Aggarwal, R. S.; Seeram, N. P.; Shishodia, S.; Takada, Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res., 2004, 24 (5A), 2783-2840.
4. Baur, J. A.; Pearson, K. J.; Price, N. L.; Jamieson, H. A.; Lerin, C.; Kalra, A.; Prabhu, V. V.; Allard, J. S.; Lopez-Lluch, G.; Lewis, K.; Pistell, P. J.; Poosala, S.; Becker, K. G.; Boss, O.; Gwinn, D.; Wang, M.; Ramaswamy, S.; Fishbein, K. W.; Spencer, R. G.; Lakatta, E. G.; Le Couteur, D.; Shaw, R. J.; Navas, P.; Puigserver, P.; Ingram, D. K.; de Cabo, R.; Sinclair, D. A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature, 2006, 444 (7117), 337-342.
5. Harikumar, K.B.; Aggarwal, B.B. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle, 2008, 7 (8), 1020-1035.
6. Raval, A. P.; Dave, K. R.; Perez-Pinzon, M. A. Resveratrol mimics ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab., 2006, 26 (9), 1141-1147.
7. Saiko, P.; Szakmary, A.; Jaeger, W.; Szekeres, T. Resveratrol and its analogs: defense against cancer, coronary disease and neurodegenerative maladies or just a fad? Mutat. Res., 2008, 658 (1-2), 68-94.
8. Vidavalur, R.; Otani, H.; Singal, P. K.; Maulik, N. Significance of wine and resveratrol in cardiovascular disease: French paradox revisited. Exp. Clin. Cardiol., 2006, 11 (3), 217-225.
9. Finkel, T.; Deng, C. X.; Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature, 2009, 460 (7255), 587-591.
10. McKinsey, T. A.; Kass, D. A. Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface. Nat. Rev. Drug Discov., 2007, 6, 617-635.
11. Verdin, E.; Dequiedt, F.; Kasler, H. G. Class II histone deactylases: versatile regulators. Trends Genet., 2003, 19, 286-293.
12. Zhang, C.; McKinsey, T.; Chang, S.; Antos, C. L.; Hill, J. A.; Olson, E. N. Class II histone deactylases act as signal-responsive repressors of cardiac hypertrophy. Cell, 2002, 110, 479-488.
13. McKinsey, T. A.; Olson, E. N. Cardiac histone acetylation -therapeutic opportunities abound. Trends Genet., 2004, 20, 206-213.
14. Iyer, A.; Fenning, A.; Lim, J.; Le, G.; Reid, R.; Halili, M.; Fairlie, D.; Brown, L. Antifibrotic activity of an inhibitor of histone deacetylases in DOCA-salt hypertensive rats. Br. J. Pharmacol., 2010, 159, 1408-1417.
15. Fenning, A.; Harrison, G.; Rose'meyer, R.; Hoey, A.; Brown, L. l-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am. J. Physiol. Heart Circ. Physiol., 2005, 289 (4), H1408-416.
16. Burstein, B.; Maguy, A.; Clement, R.; Gosselin, H.; Poulin, F.; Ethier, N.; Tardif, J. C.; Hebert, T. E.; Calderone, A.; Nattel, S. Effects of resveratrol (trans-3,5,4'-trihydroxystilbene) treatment on cardiac remodeling following myocardial infarction. J. Pharmacol. Exp. Ther., 2007, 323 (3), 916-923.
17. Lin, J. F.; Lin, S. M.; Chih, C. L.; Nien, M. W.; Su, H. H.; Hu, B. R.; Huang, S. S.; Tsai, S. K. Resveratrol reduces infarct size and improves ventricular function after myocardial ischemia in rats. Life Sci., 2008, 83 (9-10), 313-317.
18. Chen, Y. R.; Yi, F. F.; Li, X. Y.; Wang, C. Y.; Chen, L.; Yang, X. C.; Su, P. X.; Cai, J. Resveratrol attenuates ventricular arrhythmias and improves the long-term survival in rats with myocardial infarction. Cardiovasc. Drugs Ther., 2008, 22 (6), 479-485.
19. Juric, D.; Wojciechowski, P.; Das, D. K.; Netticadan, T. Prevention of concentric hypertrophy and diastolic impairment in aortic-banded rats treated with resveratrol. Am. J. Physiol. Heart Circ. Physiol., 2007, 292 (5), H2138-2143.
20. Mirkovic, S.; Seymour, A. M.; Fenning, A.; Strachan, A.; Margolin, S. B.; Taylor, S. M.; Brown, L. Attenuation of cardiac fibrosis by pirfenidone and amiloride in DOCA-salt hypertensive rats. Br. J. Pharmacol., 2002, 135 (4), 961-967.
21. Allan, A.; Fenning, A.; Levick, S.; Hoey, A.; Brown, L. Reversal of cardiac dysfunction by selective ET-A receptor antagonism. Br. J. Pharmacol., 2005, 146 (6), 846-853.
22. Sim, A. S.; Salonikas, C.; Naidoo, D.; Wilcken, D. E. Improved method for plasma malondialdehyde measurement by high-performance liquid chromatography using methyl malondialdehyde as an internal standard. J. Chromatogr. B Anal. Technol. Biomed. Life Sci., 2003, 785 (2), 337-344.
23. Litwin, S. E.; Katz, S. E.; Morgan, J. P.; Douglas, P. S. Serial echocardiographic assessment of left ventricular geometry and function after large myocardial infarction in the rat. Circulation, 1994, 89 (1), 345-354.
24. Chan, V.; Hoey, A.; Brown, L. Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats. Br. J. Pharmacol., 2006, 148 (7), 902-8.
25. Brown, L.; Duce, B.; Miric, G.; Sernia, C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J. Am. Soc. Nephrol., 1999, 10 (Suppl 11), S143-148.
26. 2+ exchange. Naunyn Schmiedebergs Arch. Pharmacol., 1991, 344 (2), 220-224.
27. Das, D. K.; Maulik, N. Resveratrol in cardioprotection: a therapeutic promise of alternative medicine. Mol. Interv., 2006, 6 (1), 36-47.
28. Das, S.; Das, D. K. Resveratrol: a therapeutic promise for cardiovascular diseases. Recent Pat. Cardiovasc. Drug Discov., 2007, 2 (2), 133-138.
29. Opie, L. H.; Lecour, S. The red wine hypothesis: from concepts to protective signalling molecules. Eur. Heart J., 2007, 28 (14), 1683-1693.
30. Das, S.; Alagappan, V. K.; Bagchi, D.; Sharma, H. S.; Maulik, N.; Das, D. K. Coordinated induction of iNOS-VEGF-KDR-eNOS after resveratrol consumption: a potential mechanism for resveratrol preconditioning of the heart. Vasc. Pharmacol., 2005, 42 (5-6), 281-289.
31. Dudley, J.; Das, S.; Mukherjee, S.; Das, D. K. Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J. Nutr. Biochem., 2009, 20 (6), 443-452.
32. Jiang, W. J. Sirtuins: novel targets for metabolic disease in drug development. Biochem. Biophys. Res. Commun., 2008, 373 (3), 341-344.
33. Alcendor, R. R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S. F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 2007, 100 (10), 1512-1521.
34. Pearson, K. J.; Baur, J. A.; Lewis, K. N.; Peshkin, L.; Price, N. L.; Labinskyy, N.; Swindell, W. R.; Kamara, D.; Minor, R. K.; Perez, E.; Jamieson, H. A.; Zhang, Y.; Dunn, S. R.; Sharma, K.; Pleshko, N.; Woollett, L. A.; Csiszar, A.; Ikeno, Y.; Le Couteur, D.; Elliott, P. J.; Becker, K. G.; Navas, P.; Ingram, D. K.; Wolf, N. S.; Ungvari, Z.; Sinclair, D. A.; de Cabo, R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab., 2008, 8 (2), 157-168.
35. Hsu, C. P.; Odewale, I.; Alcendor, R. R.; Sadoshima, J. Sirt1 protects the heart from aging and stress. Biol. Chem., 2008, 389 (3), 221-231.
36. Nicoletti, A.; Michel, J. B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc. Res., 1999, 41 (3), 532-543.
37. Rutschow, S.; Li, J.; Schultheiss, H. P.; Pauschinger, M. Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc. Res., 2006, 69 (3), 646-656.
38. Wen, Y.; Gu, J.; Peng, X.; Zhang, G.; Nadler, J. Overexpression of 12-lipoxygenase and cardiac fibroblast hypertrophy. Trends Cardiovasc. Med., 2003, 13 (4), 129-136.
39. Thandapilly, S. J.; Wojciechowski, P.; Behbahani, J.; Louis, X. L.; Yu, L.; Juric, D.; Kopilas, M. A.; Anderson, H. D.; Netticadan, T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am. J. Hypertens., 2010, 23 (2), 192-196.
40. + channels in the rat. Mol. Cell. Biochem., 2002, 237 (1-2), 1-10.
41. Momtaz, A.; Coulombe, A.; Richer, P.; Mercadier, J. J.; Coraboeuf, E. Action potential and plateau ionic currents in moderately and severely DOCA-salt hypertrophied rat hearts. J. Mol. Cell. Cardiol, 1996, 28 (12), 2511-2522.
42. + channel function by tumor necrosis factor-a: role of reactive oxygen species as a mediator. J. Biol. Chem., 2004, 279 (14), 13289-13292.
43. Potente, M.; Dimmeler, S. Emerging roles of SIRT1 in vascular endothelial homeostasis. Cell Cycle, 2008, 7 (14), 2117-2122.
44. Ota, H.; Akishita, M.; Eto, M.; Iijima, K.; Kaneki, M.; Ouchi, Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J. Mol. Cell. Cardiol, 2007, 43 (5), 571-579.